In this issue:
Screen for HBV infection during pan-oral DAAs
HBV reactivation among veterans treated with oral DAAs
Consider therapy for all patients with chronic HCV infection
Cost-effectiveness of treatment before vs after LT
Antiviral immunity after RG-101 dosing in chronic HCV infection
Explaining gender-related differences in HBV infection
Real-world effectiveness of DAAs in HCV with HCC
DAAs may improve overall survival of HCC patients
DAAs treat HCV-associated cryoglobulinaemia vasculitis
8 weeks of sofosbuvir-velpatasvirvoxilaprevir in chronic HCV infection
Please login below to download this issue (PDF)